Jounce Therapeutics Secures $56,000,000 Series B Funding
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=dd45100d-23d8-408a-bac9-6634621330cc
Date 4/23/2015
Company Name Jounce Therapeutics
Mailing Address 1030 Massachusetts Avenue Cambridge, MA 02138 USA
Company Description Jounce Therapeutics is focused on the discovery and development of first-in-class cancer immunotherapies designed to work not by treating a patient’s tumor directly, but instead by harnessing the patient’s immune system to seek out and attack cancerous cells and tumors.
Proceeds Purposes Proceeds from the financing will be used to advance Jounce’s pipeline of cancer immunotherapy programs, including moving its lead program directed at Inducible T cell Co-stimulator (ICOS) into clinical testing, as well as advancing a second program through IND-enabling studies. In addition, the investment will support expanded discovery of novel treatments aimed at tumors that may be less likely to respond to T cell checkpoint monotherapy, including therapies that target innate immune and stromal cells.